Hints and tips:
...He also has served on the board of Genzyme, the biotech company sold to Sanofi-Aventis this year for more than $20bn....
...In a research note on Monday, Cowen argued that a number of the large pharmaceutical groups, led by Eli Lilly, Sanofi-Aventis and Pfizer, would be worth more if they divested separable business units, which...
...Sanofi-Aventis has continued aggressively to acquire others, including ultimately winning support for the takeover of US group Genzyme after raising its bid above $20bn....
...Many, including Pfizer, GlaxoSmithKline and Sanofi-Aventis, are reducing research spending and closing therapy units, with the aim of boosting productivity....
...Diabetes medications still make up about 17 per cent of Lilly’s $22bn revenues, but in recent years it has lost ground to rivals such as Merck and Sanofi-Aventis....
...Sanofi-Aventis stepped up its pursuit of Genzyme on Sunday, outlining publicly its interest in a takeover deal as it inched closer to making a hostile offer for the US biotech company....
...High factory automation has helped contain V-Zug’s costs, including a smart new computerised logistics centre opened this year. “Productivity is a key success factor for us,” Mr Buhofer says....
...In pharmaceuticals, the government engineered the merger between Sanofi and Aventis to create a new champion rather than allow the Swiss Novartis to swallow it up....
...A study by a British medical journal reported that a blood-thinning pill developed by the company worked better than Plavix, a rival drug made by Sanofi-Aventis....
...The World Health Organisation on Monday said that leading vaccine producers including Novartis, GlaxoSmithKline and Sanofi-Aventis had requested “wild type virus” samples of the A (H1N1) virus....
...Then again, now that the Dutch group has flagged its interest in a takeover, Sanofi-Aventis and its rivals may come back with counter offers....
...Bernstein saw Bristol-Myers Squibb, GlaxoSmithKline and Sanofi Aventis among potential buyers of the franchise....
...His appointment comes as GlaxoSmithKline also seeks a new US head of operations, following the recent departure of Chris Viehbacher, who takes over as chief executive of Sanofi-Aventis of France at the start...
...Swiss drugmaker Novartis gained 23.7 per cent to SFr59.50 while in France, Sanofi-Aventis climbed 17.2 per cent to €44.44. Germany’s BMW was boosted by an upgrade from Goldman Sachs....
...Mr Buffett also added to his positions in Ingersoll-Rand, a maker of refrigeration gear, and Sanofi Aventis, the French drugmaker....
...Shares in Bristol-Myers Squibb fell 3.3 per cent to $27.59 after reports of a break-down in the merger talks with Sanofi-Aventis ....
...Sanofi-Aventis, the pharmaceutical group formed when Sanofi Synthelabo merged with Aventis in 2004 after the French government intervened to warn off Novartis, bought a 19.6 per cent stake from Warburg Pincus...
...But Friday’s sale comes after the Kuwait Petroleum Corporation (KPC) last year reduced its 13.5 per cent stake in Aventis following the takeover by Franco-German group Sanofi-Synthelabo....
...Sanofi-Aventis faces its own court battle over generic competition for its blood-thinning drug Plavix....
...Novartis fell 1.4 per cent to SFr69.10 amid talk that it was emerging as the leading contender but others rumoured to be interested included Roche , 1.8 per cent higher at SFr224.0, Sanofi-Aventis , 0ff...
...Other gainers included Sanofi-Aventis, up 0.9 per cent at €69.35, and Serono, 0.9 per cent firmer at SFr859....
...Shares in Novo Nordisk retreated 1.5 per cent to DKr323.50, while Novartis fell back 1.1 per cent to SFr61.65, Sanofi-Aventis eased 1.6 per cent to €70.65 and Roche lost 1.1 per cent to SFr173.60....
...It follows a bout of economic nationalism in France, where the government last year engineered the takeover of Aventis, the pharmaceuticals company, by rival Sanofi, and the bailout of engineering group...
...Sanofi-Aventis, the drugmaker, announced sales growth of 6.5 per cent in the second quarter, a little below expectations, knocking the shares 0.6 per cent to €70....
...Sanofi-Aventis, the French drugs group, tumbled 5.4 per cent to €67.30 after it said a generic-drug maker had won a summary judgement in a US court over the patent covering Sanofi’s key Lovenox stroke treatment...
International Edition